Scholars Central

Research articlePublished 26 Aug 2021

Clinical Outcomes in Metastatic Melanoma Patients Treated with Pembrolizumab: A Single-Center Retrospective Cohort Study

Authors: Sarah Mansouri, Stéphanie Marcil, Jean-Philippe Dulude, Jonathan Noujaim Liu, Guy Leblanc, Mai Kim Gervais

1Department of Medicine, Université de Montréal, Montréal, Québec, Canada; 2Division of Surgical Oncology, Hospital, Université de Montréal , Montréal, Quebec, Canada; 3Division of Medical Oncology, Maisonneuve-Rosemont Hospital, Université de Montréal, Montréal, Quebec, Canada

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Objectives: The aim of this study is to review the response rate and survival outcomes of patients with stage IV melanoma treated with pembrolizumab in our center. Methods: Patients with pathologically confirmed metastatic melanoma referred to our center from 2015 to 2017 and treated with pembrolizumab were included in this study. Follow-up consisted of clinical evaluation and FDGPET scans every 3-months. The primary outcome was the response rate of pembrolizumab. Secondary outcomes included Overall Survival (OS), Progression-Free Survival (PFS), and adverse events of pembrolizumab. Long term outcomes of patients attaining complete response for which pembrolizumab was discontinued were also analyzed. Kaplan-Meier and log-rank tests were used to calculate OS and PFS. Results: A total of 23 patients were included in the study; 7 patients had a BRAF mutation, 16 patients received The median number of pembrolizumab cycles to achieve a Complete Response (CR) was 11 cycles. Median OS and PFS were 60 months and 28 months, respectively, with a median follow-up of 27 months. At the time of data collection, 16 patients were alive and 11 of them disease free. Grade 3 and 4 adverse events occurred in less than 13% of the patients. There were no reported pembrolizumab adverse events leading to death. Conclusion: Our results confirmed the previously reported high response rates and complete responses of pembrolizumab in patients with metastatic melanoma. Patients with CR in whom treatment was discontinued remained disease-free for the duration of our follow-up.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Oncology Research and Treatment.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Oncology Research and Treatment
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Sarah Mansouri”
  • BylineArticles whose byline prints “Stéphanie Marcil”
  • BylineArticles whose byline prints “Jean-Philippe Dulude”
  • BylineArticles whose byline prints “Jonathan Noujaim Liu”
  • BylineArticles whose byline prints “Guy Leblanc”
  • BylineArticles whose byline prints “Mai Kim Gervais”